Advances in Liquid Biopsy for Diagnosis of Bladder Cancer
- PMID: 38956768
- PMCID: PMC11222820
- DOI: 10.5213/inj.2448198.099
Advances in Liquid Biopsy for Diagnosis of Bladder Cancer
Abstract
Bladder cancer (BCa) is the most common malignancy of the urinary system. It has a high recurrence rate and requires longterm follow-up. Significant advances in BCa research have been made in recent years; however, the initial diagnosis and follow-up of BCa relies on cystoscopy, which is an invasive and expensive procedure. Over the past decade, liquid biopsies (e.g., blood and urine) have proven to be highly efficient methods for the discovery of BCa biomarkers. This noninvasive sampling method is used to analyze unique tumor components released into body fluids and enables serial sampling and longitudinal monitoring of tumor progression. Several liquid biopsy biomarkers have been studied extensively and have shown promising results in the clinical applications of BCa, including early detection, microscopic residual disease detection, recurrence prediction, and treatment response. Therefore, this review aims to provide an update on various new liquid biopsy markers and the advantages and current limitations of liquid biopsy in the diagnosis of BCa.
Keywords: Blood; Diagnosis; Liquid biopsy; Urinary bladder neoplasms; Urine.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.Cell Mol Biol Lett. 2023 Apr 4;28(1):28. doi: 10.1186/s11658-023-00442-z. Cell Mol Biol Lett. 2023. PMID: 37016296 Free PMC article. Review.
-
Advances in Diagnosis and Therapy for Bladder Cancer.Cancers (Basel). 2022 Jun 29;14(13):3181. doi: 10.3390/cancers14133181. Cancers (Basel). 2022. PMID: 35804953 Free PMC article. Review.
-
Urinary extracellular vesicles: a rising star in bladder cancer management.Transl Androl Urol. 2021 Apr;10(4):1878-1889. doi: 10.21037/tau-20-1039. Transl Androl Urol. 2021. PMID: 33968676 Free PMC article. Review.
-
Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review).Int J Oncol. 2025 Mar;66(3):18. doi: 10.3892/ijo.2025.5724. Epub 2025 Feb 7. Int J Oncol. 2025. PMID: 39917986 Free PMC article. Review.
-
Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker.Int J Mol Sci. 2021 Feb 8;22(4):1713. doi: 10.3390/ijms22041713. Int J Mol Sci. 2021. PMID: 33567779 Free PMC article. Review.
Cited by
-
Investigating the relationship between peripheral blood transferrin receptor protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer.Sci Rep. 2025 Sep 1;15(1):32197. doi: 10.1038/s41598-025-12187-0. Sci Rep. 2025. PMID: 40890175 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
-
- Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, et al. Repeat transurethral resection in non-muscleinvasive bladder cancer: a systematic review. Eur Urol. 2018;73:925–33. - PubMed
-
- Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76:639–57. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous